May 6, 2013 by Brian Orelli, PhDLooking For Real Viagra? Head to the Internet.Pfizer starts selling Viagra via its website.
May 4, 2013 by Brian Orelli, PhDU.S.-Approved Obesity Drug Derailed in EUArena Pharmaceuticals and Eisai withdraw their application for obesity drug Belviq.
May 3, 2013 by Brian Orelli, PhDFDA Approves Powerful New Cholesterol DrugMerck's Liptruzet is a combination of Lipitor and Zetia.
May 2, 2013 by Brian Orelli, PhDShorter Treatments for Hepatitis C Patients on Their WayGilead demonstrates that its drug combination works in as little as eight weeks.
May 2, 2013 by Brian Orelli, PhDMerck Stock Down, Could Have Been WorseDespite a disastrous quarter, shares only fell 3%, probably because of a share repurchase program.
Apr 30, 2013 by Brian Orelli, PhD3 Investment Ideas for Biotech InvestorsEarly disruptive technology.
Apr 30, 2013 by Brian Orelli, PhDTake 2 Dividend Stocks and Call Me in the MorningHealth care and dividends are a great combination.
Apr 30, 2013 by Brian Orelli, PhDAbbott Laboratories Stock Is Half What It Used to BeThe loss of its drug division doesn't make it more appealing.
Apr 30, 2013 by Brian Orelli, PhDInvesting in Biotech Companies? Know These Names!A primer on drug names used by biotech companies.
Apr 30, 2013 by Brian Orelli, PhDHow Will Merck Stock Do After Earnings?A preview of Wednesday's earnings report.
Apr 30, 2013 by Brian Orelli, PhDWhat News Will Drive Amgen Stock Next?As a big biotech, Amgen is driven by sales and pipeline news.
Apr 29, 2013 by Brian Orelli, PhD3 Biotech Companies Ripe for a TakeoverThey've got partners potentially willing to take them out.
Apr 29, 2013 by Brian Orelli, PhDA New Diabetes Duo EmergesPfizer and Merck hook up to develop ertugliflozin.
Apr 22, 2013 by Brian Orelli, PhDHepatitis C Drugmakers Hook Up to Develop CocktailMerck and Bristol-Myers Squibb are the latest to join forces.
Apr 19, 2013 by Brian Orelli, PhDA Cystic Fibrosis Backup PlanVertex's third cystic fibrosis drug seems to work. Perhaps better than its second.
Apr 18, 2013 by Brian Orelli, PhDFDA Says, "Call Me Maybe"Sarepta still doesn't know if it should file for accelerated approval with the FDA.
Apr 17, 2013 by Brian Orelli, PhDThese Biotech Investors Are Far From DepressedAlkermes' ALKS 5461 produces positive phase 2 data in depressed patients.
